ArticleScience advances2020
A chemically unmodified agonistic DNA with growth factor functionality for in vivo therapeutic application.
Article in Science advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.
- Application of aptamers in regenerative medicine.Frontiers in bioengineering and biotechnology · 2022Pooled it
- Multivalent Aptamers: Contemporary Engineering Strategies and Biomedical Applications.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Intracellular sclerostin promotes tumor progression and metastasis as a potential therapeutic target in triple-negative breast cancer.Cell reports. Medicine · 2026Article
- Advances in aptamer technology for target-based drug discovery.Journal of pharmaceutical analysis · 2026Review
- In-cell NMR spectra of chemically unmodified RNA at physiological temperature with extended lifetime through RNase inhibitor cocktail in living human cells.Scientific reports · 2025Article
- Advancements in DNA-Driven Precision Modulation of Cell Surface Receptor for Programmable Cellular Functions.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Application of multivalent aptamers in tumor diagnosis, analysis and therapy (Review).Oncology letters · 2025Review
- Genetically Encoded Fluorogenic DNA Aptamers for Imaging Metabolite in Living Cells.Journal of the American Chemical Society · 2025Article
- Development of a Modular miRNA-Responsive Biosensor for Organ-Specific Evaluation of Liver Injury.Biosensors · 2024Article
- DNA-modulated dimerization and oligomerization of cell membrane receptors.Chemical communications (Cambridge, England) · 2024Review
- Article
- Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer.Molecular therapy. Nucleic acids · 2023Article
- Phenotypic screening of signaling motifs that efficiently induce cell proliferation.Scientific reports · 2023Article
- A neutralizable dimeric anti-thrombin aptamer with potent anticoagulant activity in mice.Molecular therapy. Nucleic acids · 2023Article
- Extracellular vesicles modulate key signalling pathways in refractory wound healing.Burns & trauma · 2023Review
- De novo selected hACE2 mimics that integrate hotspot peptides with aptameric scaffolds for binding tolerance of SARS-CoV-2 variants.Science advances · 2022Article
- Dimerization of kringle 1 domain from hepatocyte growth factor/scatter factor provides a potent MET receptor agonist.Life science alliance · 2022Article
- Article
- Sequential control of myeloid cell proliferation and differentiation by cytokine receptor-based chimeric antigen receptors.PloS one · 2022Article
- The biological applications of DNA nanomaterials: current challenges and future directions.Signal transduction and targeted therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although growth factors have great therapeutic potential because of their regenerative functions, they often have intrinsic drawbacks, such as low thermal stability and high production cost. Oligonucleotides have recently emerged as promising chemical entities for designing synthetic alternatives to growth factors. However, their applications in vivo have been recognized as a challenge because of their susceptibility to nucleases and limited distribution to a target tissue. Here, we present the first example of oligonucleotide-based growth factor mimetics that exerts therapeutic effects at a target tissue after systemic injection. The aptamer was designed to dimerize a growth factor receptor for its activation and mitigated the progression of Fas-induced fulminant hepatitis in a mouse model. This unprecedented functionality of the aptamer can be reasonably explained by its high nuclease stability and migration to the liver parenchyma. These mechanistic analyses provided insights for the successful application of aptamer-based receptor agonists.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.